Novel approach to overcome resistance to cancer drugs
Researchers at the University of Queensland have discovered a promising drug target capable of addressing drug resistance and preventing tumour regrowth in cancer patients.
List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
Researchers at the University of Queensland have discovered a promising drug target capable of addressing drug resistance and preventing tumour regrowth in cancer patients.
Human derived induced pluripotent stem cells (hiPSCs) have revolutionised research and are increasingly used for toxicology screening and disease modelling. Early detection of neurotoxicity induced by potential new therapies is a major challenge, and hiPSC-neuronal cells may provide a solution. These cells demonstrate considerable promise for uncovering drug-induced perturbations to…
Organoids, lab-grown 3D structures that mimic human organs, are redefining preclinical research through bypassing the ethical and practical limitations of animal models. Technological advancements in organoid research, including automation and improved analytical tools, promise to unlock new possibilities by streamlining the application of these 3D structures to enhance drug development…
This article discusses the need for adulticidal drugs to treat Onchocerca volvulus infections, a parasite causing onchocerciasis (river blindness), as the current treatment with ivermectin and surgery presents challenges for affected communities. It highlights research findings on the potential of analgesic medicines to target adult worms and emphasises the importance…
Rob Scoffin and Matthew Habgood from solutions provider Cresset look to the future of drug discovery and the roles that artificial intelligence and machine learning could play.
Infectious agents' drug resistance is a complex challenge affecting survival. Understanding their mechanisms in vectors, the potential of plant-derived treatments, and roles of nucleic acids and biochemical compounds is crucial for effective therapy, requiring collaborative international research through the One Health Initiative.
We are thrilled to announce the winner of the Drug Target Review x ELRIG's Article Competition: Dr Rosa Woldegebriel, Lead Scientist at the Human Centric Drug Discovery in Oxford, UK, whose article titled "Advancing Drug Discovery for Pain Disorders: Human iPSC-Based Approach" presents a revolutionary method in pharmaceutical research. Addressing…
Join us for our monthly Women in STEM series where we showcase and celebrate the achievements of inspiring women in the field. This month we interview Theonie Anastassiadis, Cofounder & Chief Innovation Officer of Alltrna and Senior Principal of Flagship Pioneering. As a senior principal at Flagship Pioneering, Theonie conceives,…
Meet RRx-001 (nibrozetone) and AdAPT-001—two cutting-edge compounds crafted by EpicentRx. In this Q&A session with Dr Bryan Oronsky, Chief Development Officer at EpicentRx, we discover novel mechanisms, diverse applications, and game-changing impact on cancer treatment and beyond.
24 August 2023 | By Bio-Rad Laboratories Inc.
Watch our industry experts to learn about the tangible benefits and best practice of custom flow cytometry automation projects. You’ll discover how to reduce your challenges implementing tailored automation, controlling the quality of the data produced and improving the reliability of your data acquisition.
In this exclusive interview with Young Kwon, CEO of Alchemab, we discuss new platforms that are revolutionising how researchers identify naturally occurring antibodies in resilient individuals, opening up new possibilities for the development of disease-modifying therapies.
Researchers at the RIKEN Center for Sustainable Research Science (CSRS) and the University of Toronto have discovered a method to combat fungal infections by targeting their fatty acid production.
As the NHS celebrates its 75th anniversary, healthcare leaders, policymakers, and practitioners have been sharing their innovative ideas on how to reshape and safeguard its future.
Researchers provide new insights into viral evolution and have significant implications for understanding and predicting the behaviour of influenza and other mutating diseases.
The potential of precision medicine requires a small shift in perspective, Patrick Short, CEO and co-founder of Sano Genetics, explains in this Q&A.